NASDAQ:EGLT Egalet (EGLT) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0080▼$0.008050-Day Range$0.01▼$0.3352-Week Range$0.03▼$1.57VolumeN/AAverage Volume853,425 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Egalet alerts: Email Address Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Egalet Stock (NASDAQ:EGLT)Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.Read More Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades EGLT Stock News HeadlinesAugust 16, 2022 | prnewswire.comThe Worldwide Opioids Industry is Expected to Reach $6.29 Billion by 2027 - PR NewswireAugust 16, 2022 | finance.yahoo.comInsights on the Opioids Global Market to 2027 - Increasing Investments in R&D in Healthcare Presents Opportunities - Yahoo FinanceJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.August 12, 2022 | businesswire.comGlobal Opioids Market (2022 to 2027) - Players Include Pfizer, Purdue Pharmaceuticals, Rhodes Technologies and Sun Pharmaceutical Industries - ResearchAndMarkets.com - Business WireJuly 28, 2022 | finance.yahoo.comDrug Taste Masking and Taste Assessment Services and Technologies Markets, 2035 - Yahoo FinanceJuly 28, 2022 | globenewswire.comDrug Taste Masking and Taste Assessment Services and Technologies Markets, 2035 - GlobeNewswireJuly 26, 2022 | businesswire.comGlobal Drug Taste Masking and Taste Assessment Services and Technologies Market Report 2022-2035 - ResearchAndMarkets.com - Business WireJuly 25, 2022 | prnewswire.comGlobal Drug Taste Masking and Taste Assessment Services and Technologies Market Report 2022: Oral Solid Dosage Market is the Largest Segment, Anticipated to Reach Over $900 Billion by 2027 - PR NewswireJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 20, 2022 | businesswire.comGlobal Osteoporosis Therapeutics Market to 2027 - Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth - ResearchAndMarkets.com - Business WireMay 20, 2022 | benzinga.comGlobal Osteoporosis Therapeutics Market to 2027 - Rising Prevalence of Osteoporosis in Post-menopausal Wo - BenzingaMay 15, 2022 | globenewswire.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - GlobeNewswireMarch 17, 2022 | businesswire.comGlobal Opioid Market Outlook to 2028: Oxycodone Segment is Estimated to Grow at Significant Pace During Forecast Period - ResearchAndMarkets.com - Business WireMarch 14, 2022 | benzinga.comNasal Spray Market Size Global Industry Share, Industry Growth, Competitive Landscape, Recent Development - BenzingaMarch 14, 2022 | globenewswire.comNasal Spray Market Size Global Industry Share, Industry Growth, Competitive Landscape, Recent Developments, Regional Outlook and Forecast by 2029 - GlobeNewswireMarch 10, 2022 | streetinsider.comForm 10-K Assertio Holdings, Inc. For: Dec 31 - StreetInsider.comMarch 10, 2022 | globenewswire.comPostoperative Pain Management Market growth is predicted at 5% CAGR to reach a valuation of US$ 57.8 Bn by 2031 - GlobeNewswireMarch 10, 2022 | benzinga.comPostoperative Pain Management Market growth is predicted at 5% CAGR to reach a valuation of US$ 57.8 Bn b - BenzingaSee More Headlines Receive EGLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Egalet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2018Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EGLT CUSIPN/A CIK1586105 Webwww.egalet.com Phone610-833-4200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert S. Radie (Age 55)Pres, CEO & Director Mr. Stanley J. Musial (Age 57)Exec. VP, CFO & Sec. Dr. Mark Strobeck (Age 47)Exec. VP & COO Ms. Barbara A. Carlin (Age 43)Sr. VP & Chief Accounting Officer Dr. Karsten Lindhardt M.Sc. (Age 46)Ph.D., Chief Scientific Officer Key CompetitorsAesther Healthcare AcquisitionNASDAQ:AEHAWBioLingus (Cayman)NASDAQ:SUBLEvelo BiosciencesNASDAQ:EVLOGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXView All Competitors EGLT Stock Analysis - Frequently Asked Questions How were Egalet's earnings last quarter? Egalet (NASDAQ:EGLT) issued its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.06. The specialty pharmaceutical company had revenue of $7.44 million for the quarter, compared to analysts' expectations of $8.64 million. What other stocks do shareholders of Egalet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Egalet investors own include Novavax (NVAX), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Ocular Therapeutix (OCUL), Trevena (TRVN) and Overstock.com (OSTK). This page (NASDAQ:EGLT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Egalet Please log in to your account or sign up in order to add this asset to your watchlist. Share Egalet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.